[关键词]
[摘要]
目的 研究培元通脑胶囊联合依达拉奉注射液治疗急性脑梗死的临床疗效。方法 选取2015年10月—2018年10月海口市人民医院收治的80例急性脑梗死患者为研究对象,将所有患者随机分为对照组和治疗组,每组各40例。对照组患者静脉滴注依达拉奉注射液30 mg/次,加入适量生理盐水中稀释后,30 min内滴完,2次/d;治疗组在对照组基础上口服培元通脑胶囊,3粒/次,3次/d。两组患者均接受治疗14 d。观察两组的临床疗效,比较两组的美国国立卫生研究院卒中量表(NIHSS)评分、Barthel(BI)指数评分、血清炎性因子水平。结果 治疗后,对照组和治疗组的总有效率分别为77.50%、92.50%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者NIHSS评分明显降低,BI指数评分显著升高,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组NIHSS评分和BI指数评分明显优于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)水平均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组血清炎性因子水平明显低于对照组,两组比较差异有统计学意义(P<0.05)。结论 培元通脑胶囊联合依达拉奉注射液治疗急性脑梗死具有较好的临床疗效,能改善患者神经功能和日常生活能力,降低血清炎性因子水平,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To study the effect of Peiyuan Tongnao Capsules combined with Edaravone Injection in treatment of acute cerebral infarction. Methods Patients (80cases) with acute cerebral infarction in Haikou People's Hospital from October 2015 to October 2018 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were iv administered with Edaravone Injection, 30 mg added into appropriate normal saline, and completed the drip in 30 mi, twice daily. Patients in the treatment group were po administered with Peiyuan Tongnao Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and NIHSS scores, BI index scores, and the serum levels of inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.50% and 92.50%, respectively, and there was difference between two groups (P<0.05). After treatment, the NIHSS scores in two groups were significantly decreased, but the BI index scores in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of hs-CRP, IL-6, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum levels of inflammatory factors in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Peiyuan Tongnao Capsules combined with Edaravone Injection has clinical curative effect in treatment of acute cerebral infarction, can improve the neurological function and daily living ability of patients, and reduce the serum level of inflammatory factors, which has a certain clinical application value.
[中图分类号]
[基金项目]